Michael C. Quirk - 10 Apr 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Scientific Officer and Interim Head of R&D
Signature
Brandon Marsh, attorney in fact for Michael C. Quirk
Issuer symbol
SAGE
Transactions as of
10 Apr 2025
Transactions value $
-$5,086
Form type
4
Filing time
11 Apr 2025, 16:09:46 UTC
Previous filing
02 Apr 2025
Next filing
26 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +933 +3.21% $0.00 30K 10 Apr 2025 Direct F1
transaction SAGE Common Stock Tax liability -$2.16K -312 -1.04% $6.91 29.7K 10 Apr 2025 Direct
transaction SAGE Common Stock Award $0 +1.27K +4.27% $0.00 31K 10 Apr 2025 Direct F2
transaction SAGE Common Stock Tax liability -$2.93K -424 -1.37% $6.91 30.6K 10 Apr 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 2,666 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 933 shares.
F2 On October 3, 2022, the reporting person was granted PSUs to acquire a total of 3,625 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 1,269 shares.

Remarks:

Chief Scientific Officer and Interim Head of R&D